Market news
iShares offers lower fees and concentrated biotech exposure with stronger 1-year returns, while Simplify provides broader healthcare diversification and a higher dividend yield.
iShares offers lower fees and concentrated biotech exposure with stronger 1-year returns, while Simplify provides broader healthcare diversification and a higher dividend yield.
XLV offers exposure to the broader healthcare sector, while IBB targets biotech innovators. Here's how the two stack up on risk, returns, and diversification.
Smart Beta ETF report for IBB
IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the volatility and a 1.5% dividend yield.
First Trust's 30-stock strategy delivered 53.2% returns over one year, but comes with higher concentration risk and a steeper 11-basis-point fee.
Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.
Smart Beta ETF report for FBT
Broad healthcare diversification or concentrated biotech growth? Compare cost, risk, and portfolio composition to find your fit.
This is the newest page. Registered accounts read further back.